COPENHAGEN, March 26 - Novo Nordisk on Thursday appointed Poul Weihrauch, the chief executive of family-owned U.S. confectionery and pet food company Mars, as an observer to its board, the drugmaker said at its annual general meeting.
The appointment was announced alongside shareholder votes that brought three new directors onto the board: pharmaceutical industry figures Jan van de Winkel and Ramona Sequeira, and Helena Saxon, who serves on the board of fashion retailer H&M. Novo Nordisk is the manufacturer of the weight-loss drug Wegovy, and the company framed the changes as part of efforts to strengthen its position in the highly competitive U.S. obesity market.
Company officials noted that these governance changes follow a broader leadership reorganisation carried out in 2025 together with the Novo Nordisk Foundation, the firms majority shareholder. That reorganisation included replacing the chief executive and reshaping the board. As part of that process, Lars Rebien Sorensen, who also chairs the Foundation, was named board chairman, consolidating his leadership role.
Under the new management team, Novo Nordisk is pursuing a set of initiatives designed to boost its consumer credentials in the United States. In January the company launched a pill form of Wegovy across multiple cash-pay channels rather than limiting distribution to traditional insurance pathways. Novo has said it will increase its focus on telehealth, deepen retail partnerships and expand direct-to-consumer access, reflecting the companys view - shared with chief rival Eli Lilly and Co - that the obesity market is becoming more "consumer-like."
The appointments and strategic shifts come as Novo seeks to better position itself amid intensifying competition in obesity treatments and changing routes to patient access. Shareholder approval of the new board members and the observer role were confirmed during the annual meeting.
About third-party evaluation mentioned during the meeting
The meeting materials also referenced ProPicks AI, which evaluates NOVOb using more than 100 financial metrics and assesses stocks for risk-reward based on current data. The materials cited ProPicks AIs prior notable selections, naming Super Micro Computer (+185%) and AppLovin (+157%) as examples, and indicated that ProPicks AI reviews NOVOb alongside thousands of other companies to identify investment ideas.
Contextual note
The companys moves at the governance and commercial levels reflect an emphasis on consumer channels and distribution models as part of its strategy in the U.S. obesity market. Shareholder-elected board additions and the appointment of an industry outsider as a board observer form part of that broader reorientation.